- Home
- TOVX
as 12-18-2024 11:43am EST
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | ROCKVILLE |
| Market Cap: | 3.5M | IPO Year: | 2006 |
| Target Price: | $6.00 | AVG Volume (30 days): | 102.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -32.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.14 - $17.00 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Theriva Biologics Inc. News
TOVX Breaking Stock News: Dive into TOVX Ticker-Specific Updates for Smart Investing
GlobeNewswire
13 days ago
Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer
Associated Press Finance
a month ago
Theriva Biologics: Q3 Earnings Snapshot
GlobeNewswire
2 months ago
Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech Grant
MT Newswires
2 months ago
Theriva Biologics Gets EU Orphan Drug Designation for Eye Cancer Treatment Candidate; Shares Rise
GlobeNewswire
2 months ago
Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma
MT Newswires
2 months ago
Theriva Shares Jump After Company Gets Recommendation to Continue SYN-004 Trial
Benzinga
3 months ago
Nano-Cap Theriva Biologics' Investigational Drug For Transplant-Related Complication Shows Safety In Bone Marrow Transplant Patients
GlobeNewswire
3 months ago
Theriva™ Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
Compare TOVX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TOVX Theriva Biologics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.